EGFR activation elicited adaptive resistance to lorlatinib in ALK-rearranged non-small cell lung cancer cells

被引：0
|
作者：
Katayama, Yuki [1 ]
Yamada, Tadaaki [1 ]
Tanimura, Keiko [1 ]
Morimoto, Kenji [1 ]
Yoneda, Kazue [2 ]
Horinaka, Mano [3 ]
Sakai, Toshiyuki [3 ]
Ozasa, Hiroaki [4 ]
Takayama, Koichi [1 ]
机构：
[1] Kyoto Prefectural Univ Med, Dept Pulm Med, Grad Sch Med Sci, Kyoto, Japan
[2] Hyogo Coll Med, Dept Omics Med, Nishinomiya, Hyogo, Japan
[3] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Drug Discovery Med, Kyoto, Japan
[4] Kyoto Univ, Grad Sch Med, Dept Resp Med, Kyoto, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO38-3
引用
收藏
页码：S1421 / S1421
页数：1
相关论文
共 50 条
  • [41] Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
    Kate McKeage
    Drugs, 2015, 75 : 75 - 82
  • [42] ALK-rearranged non-small cell lung cancer is associated with a high rate of venous thromboembolism
    Zer, A.
    Hershko-Klement, A.
    Hwang, D.
    Korpanty, G.
    Leighl, N.
    Liu, G.
    Feld, R.
    Burkes, R.
    Tsao, M.
    Shepherd, F.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S134 - S134
  • [43] Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
    McKeage, Kate
    DRUGS, 2015, 75 (01) : 75 - 82
  • [44] Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions
    Cameron, Laird
    Solomon, Benjamin
    DRUGS, 2015, 75 (10) : 1059 - 1070
  • [45] Cardiac Toxicity of Crizotinib Therapy in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
    Zhang, Yan
    Wang, Yan
    Li, Junling
    Hao, Xuezhi
    Ma, Di
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S377 - S377
  • [46] Immunotherapy for ALK-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches
    Sankar, Kamya
    Nagrath, Sunitha
    Ramnath, Nithya
    CANCERS, 2021, 13 (06)
  • [47] Diverse clinical outcomes for the EGFR-mutated and ALK-rearranged advanced non-squamous non-small cell lung cancer
    Lin, Chun-Wei
    Huang, Kuo-Yang
    Lin, Ching-Hsiung
    Hou, Ming-Hon
    Lin, Sheng-Hao
    ONCOLOGY LETTERS, 2025, 29 (03)
  • [48] Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
    Recondo, Gonzalo
    Mezquita, Laura
    Facchinetti, Francesco
    Planchard, David
    Gazzah, Anas
    Bigot, Ludovic
    Rizvi, Ahsan Z.
    Frias, Rosa L.
    Thiery, Jean Paul
    Scoazec, Jean-Yves
    Sourisseau, Tony
    Howarth, Karen
    Deas, Olivier
    Samofalova, Dariia
    Galissant, Justine
    Tesson, Pauline
    Braye, Floriane
    Naltet, Charles
    Lavaud, Pernelle
    Mahjoubi, Linda
    Abou Lovergne, Aurelie
    Vassal, Gilles
    Bahleda, Rastilav
    Hollebecque, Antoine
    Nicotra, Claudio
    Ngo-Camus, Maud
    Michiels, Stefan
    Lacroix, Ludovic
    Richon, Catherine
    Auger, Nathalie
    De Baere, Thierry
    Tselikas, Lambros
    Solary, Eric
    Angevin, Eric
    Eggermont, Alexander M.
    Andre, Fabrice
    Massard, Christophe
    Olaussen, Ken A.
    Soria, Jean-Charles
    Besse, Benjamin
    Friboulet, Luc
    CLINICAL CANCER RESEARCH, 2020, 26 (01) : 242 - 255
  • [49] Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series
    Myall, Nathaniel J.
    Lei, Amy Q.
    Wakelee, Heather A.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (01) : 487 - 495
  • [50] Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer
    Sakashita, Takuya
    Yanagitani, Noriko
    Koike, Sumie
    Low, Siew-Kee
    Takagi, Satoshi
    Baba, Satoko
    Takeuchi, Kengo
    Nishio, Makoto
    Fujita, Naoya
    Katayama, Ryohei
    CANCER SCIENCE, 2022, 113 (11) : 3888 - 3900
12345